Stockscreener 앱 받기
162.70
1.26%
-2.07
시간 외 거래:
163.00
0.30
+0.18%
전일 마감가:
$164.77
열려 있는:
$162.82
하루 거래량:
3.07M
Relative Volume:
1.00
시가총액:
$252.33B
수익:
$60.48B
순이익/손실:
$10.40B
주가수익비율:
48.86
EPS:
3.3297
순현금흐름:
$8.05B
1주 성능:
+0.00%
1개월 성능:
+4.55%
6개월 성능:
-19.27%
1년 성능:
+98.95%
1일 변동 폭
$161.13
$163.78
1주일 범위
$160.87
$165.74
52주 변동 폭
$72.89
$212.71
아스트라제네카 ADR Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
162.70 | 255.11B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,149.36 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
275.23 | 644.33B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
256.46 | 462.68B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
150.33 | 367.58B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
159.99 | 296.97B | 54.66B | 13.58B | 16.05B | 7.0171 |
아스트라제네카 ADR Stock (AZN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-27 | 개시 | Citigroup | Buy |
| 2025-10-27 | 재개 | Jefferies | Buy |
| 2025-10-16 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2025-04-15 | 개시 | Exane BNP Paribas | Outperform |
| 2025-02-13 | 업그레이드 | UBS | Neutral → Buy |
| 2025-02-12 | 개시 | Morgan Stanley | Overweight |
| 2024-11-20 | 업그레이드 | UBS | Sell → Neutral |
| 2024-11-06 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-09-13 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2024-04-16 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-02-08 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 개시 | Morgan Stanley | Overweight |
| 2024-01-16 | 재개 | UBS | Sell |
| 2024-01-03 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-12-18 | 개시 | HSBC Securities | Buy |
| 2023-09-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-07-12 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-05 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-04-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2022-09-15 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | 업그레이드 | Argus | Hold → Buy |
| 2022-06-14 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-11 | 업그레이드 | DZ Bank | Sell → Hold |
| 2021-12-07 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-08-12 | 재개 | JP Morgan | Overweight |
| 2021-04-12 | 다운그레이드 | Argus | Buy → Hold |
| 2021-03-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-02-25 | 업그레이드 | UBS | Neutral → Buy |
| 2021-01-15 | 개시 | Deutsche Bank | Buy |
| 2020-12-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | 업그레이드 | UBS | Sell → Neutral |
| 2020-11-11 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2019-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-10-25 | 업그레이드 | Liberum | Hold → Buy |
| 2019-04-02 | 다운그레이드 | UBS | Neutral → Sell |
| 2019-02-05 | 개시 | Exane BNP Paribas | Outperform |
| 2019-01-25 | 업그레이드 | Shore Capital | Hold → Buy |
| 2018-12-11 | 재개 | Jefferies | Hold |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-08-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2018-03-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-02-06 | 재확인 | Leerink Partners | Mkt Perform |
| 2018-02-05 | 재확인 | Bernstein | Outperform |
| 2018-01-18 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-12-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2017-10-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
모두보기
아스트라제네카 ADR 주식(AZN)의 최신 뉴스
AstraZeneca stock heads into the open after a 0.3 percent gain - AD HOC NEWS
Radioligand Therapy Market to Grow from USD 2.98 Billion in 2025 to USD 15.85 Billion by 2035, at a CAGR of 18.2% - GlobeNewswire Inc.
AstraZeneca stock gains on FDA breast cancer approval and analyst support - AD HOC NEWS
AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah - The Globe and Mail
Citi backs AstraZeneca sentiment boost after Etcamah wins accelerated FDA approval - Proactive financial news
AstraZeneca stock gains on analyst support and July results - AD HOC NEWS
Why Is AstraZeneca (LSE:AZN) Back in Focus After Fresh Regulatory News? - Kalkine Media
AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah - Zacks Investment Research
FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer - pharmaceutical-technology.com
AstraZeneca's breast cancer drug granted accelerated approval in the US - Sharecast.com
AstraZeneca PLC : Gets a Buy rating from JP Morgan - marketscreener.com
AstraZeneca’s Etcamah Approved In US For ESR1-mutated Advanced Breast Cancer - directorstalkinterviews.com
REGAstraZeneca PLCEtcamah approved in the US for HR+ breast cancer - tradingview.com
A green light from the US FDA for AstraZeneca in breast cancer - marketscreener.com
AstraZeneca PLC : Jefferies reaffirms its Buy rating - marketscreener.com
AstraZeneca stock heads into the open after a 1.15 percent drop - AD HOC NEWS
IN BRIEF: AstraZeneca wins US nod for Etcamah breast cancer combo - London South East
AstraZeneca stock reacts as FDA grants accelerated approval for new breast cancer pill - AD HOC NEWS
AstraZeneca's Etcamah Combination Authorized for Advanced Breast Cancer Treatment in US - marketscreener.com
AstraZeneca’s breast cancer pill gets FDA approval - The Seattle Times
AstraZeneca's Breast Cancer Pill Gets Approval From The FDA - NDTV Profit
FDA Clears AstraZeneca's Breast Cancer Pill Etcamah - Briefs Finance
AstraZeneca’s Breast Cancer Pill Gets Approval From the FDA - Bloomberg.com
AstraZeneca wins approval of camizestrant for breast cancer (NYSE:AZN) - Seeking Alpha
AstraZeneca slides Friday, underperforms market - MarketWatch
AstraZeneca: Share price weakness of late, should be capitalised on - marketscreener.com
AstraZeneca settles Texas case for $34 million - BioXconomy
The Zacks Analyst Blog Highlights AMD, Costco, AstraZeneca, Peoples Bancorp of North Carolina and Spruce Power - Yahoo Finance
AstraZeneca PLC : Deutsche Bank reiterates its Sell rating - marketscreener.com
Key facts: AstraZeneca PLC buys ZEGFROVY; EU OK Enhertu; Tagrisso PFS - tradingview.com
AstraZeneca (AZN) lifts share count to 1.55B after employee share issues - Stock Titan
All AstraZeneca (AZN) shares carry votes on 1.55B total - Stock Titan
AstraZeneca acquires ZEGFROVY rights for $600 million - grafa.com
AstraZeneca lists €2.55B euro notes in London | AZN SEC FilingForm 6-K - Stock Titan
AstraZeneca gets EU OK for Enhertu 1st-line breast cancer | AZN SEC FilingForm 6-K - Stock Titan
Wan Ling Martello to join AstraZeneca (AZN) board in 2026, bringing experience from Nestlé, Walmart and Alibaba. - Stock Titan
AstraZeneca pays $600m for global Zegfrovy rights | AZN SEC FilingForm 6-K - Stock Titan
AstraZeneca lung cancer combo extends time to progression | AZN SEC FilingForm 6-K - Stock Titan
AstraZeneca unveils Zegfrovy deal, lung trial win and Enhertu approval - marketscreener.com
AstraZeneca subsidiary lists €2.55bn bonds on LSE - Investing.com
AstraZeneca PLC : JP Morgan reaffirms its Buy rating - marketscreener.com
AstraZeneca and HUTCHMED report Phase III results for Tagrisso-Orpathys combination - Yahoo Finance UK
AstraZeneca PLC (AZN) Stock Analysis: Unraveling a 30.63% Potential Upside Within the Healthcare Sector - directorstalkinterviews.com
AstraZeneca Completes License Agreement for Lung Cancer Treatment - marketscreener.com
AstraZeneca completes global license agreement for oral EGFR inhibitor Zegfrovy for lung cancer - AstraZeneca
AstraZeneca Loses Suit Seeking Block on Colorado Pharmacy Law - Bloomberg Government News
AstraZeneca (AZN) Tezspire improves swallowing symptoms in Phase III trial - Stock Titan
AstraZeneca slides Wednesday, underperforms market - MarketWatch
AstraZeneca (AZN) lines up €2.55B in new Eurobonds - Stock Titan
Key facts: AstraZeneca (AZN) talks stall; €2.55bn bond, $198 PT - tradingview.com
AstraZeneca prices €2.55bn euro bond sale across four tranches - Yahoo Finance UK
아스트라제네카 ADR (AZN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.55%
자본화:
|
볼륨(24시간):